Citigroup cuts ACADIA Pharmaceuticals target to $33 after trial miss
AI Summary
Citigroup lowered ACADIA Pharmaceuticals’ price target after remlifanserin missed its trial goal.
ACADIA shares dropped 10.5% following the mid-stage trial result.
Citigroup retained its Buy rating on ACADIA Pharmaceuticals.
Citigroup lowered its price target for ACADIA Pharmaceuticals to $33 from $40 after the company’s Alzheimer's drug remlifanserin missed the primary goal in a mid-stage trial. ACADIA shares fell 10.5%, while Citigroup maintained its Buy rating.
The information on this website is generated using AI and we cannot guarantee its accuracy.
Please use it as reference information only.